OncoMatch/Clinical Trials/NCT06612580

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Is NCT06612580 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-AAZTA-NI-093 for prostate cancer (adenocarcinoma).

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06612580Data as of May 2026

Treatment: 68Ga-AAZTA-NI-093 — 68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify